menu
    • menu
    [{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aumolertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hansoh Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ EQRx","highestDevelopmentStatusID":"12","companyTruncated":"Hansoh Pharma \/ EQRx"},{"orgOrder":0,"company":"EQRx","sponsor":"CM Life Sciences","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Merger","leadProduct":"Aumolertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2,"dosageForm":"Tablet","sponsorNew":"EQRx \/ CM Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CM Life Sciences"},{"orgOrder":0,"company":"EQRx","sponsor":"Abdul Latif Jameel Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Aumolertinib","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Abdul Latif Jameel Health","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Abdul Latif Jameel Health"},{"orgOrder":0,"company":"EQRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aumolertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Aumolertinib

    Menu

    Aumolertinib

    DEVELOPMENTS

    INTERMEDIATES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EQRx

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

                            Details : Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.

                            Brand Name : EQ143

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 29, 2022

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EQRx

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Abdul Latif Jameel Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in...

                            Details : Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

                            Brand Name : EQ143

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 22, 2021

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Abdul Latif Jameel Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EQRx

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : CM Life Sciences

                            Deal Size : $2,000.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III

                            Details : Proceeds expand balance sheet to ~$2.0 billion and will be used for “new pharma” platforms. EQRx’s growing pipeline includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and other cli...

                            Brand Name : EQ143

                            Molecule Type : Small molecule

                            Upfront Cash : $2,000.0 million

                            August 06, 2021

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : CM Life Sciences

                            Deal Size : $2,000.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hansoh Pharma

                            China arrow
                            Discovery on Target
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : EQRx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib

                            Details : Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $100.0 million

                            July 23, 2020

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : EQRx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth